A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf
.
Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States
2020
Figshare
Objective: To evaluate the relative cost-effectiveness of tildrakizumab and other biologic and targeted systemic treatments compared with a mix of topical therapies, phototherapies, and other conventional systemic therapies as first-line treatment for moderate-to-severe plaque psoriasis from a United States payer's perspective. Methods: A Markov model consisting of health states based on Psoriasis Area Severity Index (PASI) response rate categories and death was developed. The probabilities of
doi:10.6084/m9.figshare.12601267
fatcat:wtlgxhvovremzjhtdsbslokjtu